Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGF1 known ✓ | P05230 | 1/20 | 0.46 |
| ▸ | CA12 known ✓ | O43570 | 1/20 | 0.39 |
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.39 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.39 |
| ▸ | THRB known ✓ | P10828 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | POLB | P06746 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 2/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.40 |
| ▸ | PKM | P14618 | 2/20 | 0.40 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3897326 | 0.87 | SIRT1 (0.48) | SIRT1PRMT1FGF1KDM4EGAA | |
| SCHEMBL3895105 | 0.83 | NT5E (0.56) | SIRT1PRMT1KDM4EGAAMEN1 | |
| SCHEMBL3895091 | 0.82 | NT5E (0.55) | SIRT1PRMT1KDM4EGAAMEN1 | |
| SCHEMBL3899960 | 0.81 | POLB (0.47) | SIRT1PRMT1KDM4EGAAMEN1 | |
| SCHEMBL11432535 | 0.80 | FGF1 (0.43) | SIRT1PRMT1FGF1KDM4EGAA | |
| SCHEMBL11763828 | 0.78 | FGF1 (0.55) | SIRT1PRMT1FGF1KDM4EGAA | |
| SCHEMBL11437672 | 0.74 | RORC (0.43) | SIRT1PRMT1FGF1KDM4EMEN1 | |
| Naphthalene Trisulfonate SCHEMBL306175 | 0.73 | SIRT1 (0.47) | SIRT1PRMT1FGF1KDM4EMEN1 | |
| Naphthalene Trisulfonate SCHEMBL29381206 | 0.73 | SIRT1 (0.47) | SIRT1PRMT1FGF1KDM4EMEN1 | |
| SCHEMBL11766327 | 0.73 | RAB9A (0.54) | FGF1GAAMEN1POLBBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7572459-B2 | Prevention infections in humans, animals | STARPHARMA PTY LTD. (AU) | 2009-08-11 | — | — | US | disclosed |
| EP-1113806-B1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA PTY LTD (AU) | 2007-09-05 | — | — | EP | disclosed |
| EP-0927217-B1 | ANGIOGENIC INHIBITORY COMPOUNDS | STARPHARMA PTY LTD (AU) | 2006-05-03 | — | — | EP | disclosed |
| EP-1113805-A4 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LTD (AU) | 2004-05-19 | — | — | EP | disclosed |
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | STARPHARMA LIMITED | 2003-07-10 | — | — | US | disclosed |
| EP-1113806-A4 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LTD (AU) | 2003-06-25 | — | — | EP | disclosed |
| EP-0927217-A4 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RES INST LTD (AU) | 2003-04-23 | — | — | EP | disclosed |
| US-6464971-B1 | ANIONIC-CONTAINING MOIETY IS A NEURAMINIC- OR SIALIC ACID-CONTAINING. MOIETY, IT IS MODIFIED IN THE 4-POSITION BY SUBSTITUTION WITH AN AMINO, AMIDO, CYANO, AZIDO OR GUANIDO GROUP, OR IS UNSATURATED. | STARPHARMA LIMITED (AU) | 2002-10-15 | — | — | US | disclosed |
| US-6426067-B1 | CARDIOVASCULAR DISORDERS; ANTITUMOR AGENTS | BIOMOLECULAR RESEARCH INSTITUTE, LTD. (AU) | 2002-07-30 | — | — | US | disclosed |
| EP-1113805-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | disclosed |
| EP-1113806-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | Starpharma Limited (AU) | 2001-07-11 | — | — | EP | disclosed |
| WO-2000015240-A1 | ANIONIC OR CATIONIC DENDRIMER ANTIMICROBIAL OR ANTIPARASITIC COMPOSITIONS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| WO-2000015239-A1 | INHIBITION OF TOXIC MATERIALS OR SUBSTANCES USING DENDRIMERS | STARPHARMA LIMITED (AU) | 2000-03-23 | — | — | WO | disclosed |
| EP-0927217-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998003573-A1 | ANGIOGENIC INHIBITORY COMPOUNDS | BIOMOLECULAR RESEARCH INSTITUTE LTD. (AU) | 1998-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030129158-A1 | Anionic or cationic dendrimer antimicrobial or antiparasitic compositions | FUT6, B3GNT2, SIGLEC7 | FGF1 4540/4885CA12 960/4885CA1 2006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.